Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression

por Kim, Hyun Jung, Lee, Sukmook, Oh, Yong-Seok, Chang, Ha Kyun, Kim, Young Sang, Hong, Sung Hee, Kim, Jung Yong, Park, Young-Whan, Lee, Song-Jae, Song, Seong-Won, Kim, Jung Ju, Heo, Kyun
Publicado 2019

Preclinical development of a humanized neutralizing antibody targeting HGF

por Kim, Hyori, Hong, Sung Hee, Kim, Jung Yong, Kim, In-Chull, Park, Young-Whan, Lee, Song-Jae, Song, Seong-Won, Kim, Jung Ju, Park, Gunwoo, Kim, Tae Min, Kim, Yun-Hee, Park, Jong Bae, Chung, Junho, Kim, In-Hoo
Publicado 2017

Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

por Kim, Hark Kyun, Kang, Jeong Won, Park, Young‐Whan, Kim, Jung Young, Kim, Minchae, Kim, Soo Jin, Kim, Se‐mi, Ho Ryu, Keun, Yoon, Seonghae, Kim, Yun, Cho, Joo‐Youn, Lee, Keun Seok, Yun, Tak, Kim, Kiwon, Kwak, Mi Hyang, Kim, Tae‐Sung, Chung, Jinsoo, Park, Joong‐Won
Publicado 2020

First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

por Kim, Seung Tae, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Whan, Park, Neunggyu, Lee, Hukeun, Hong, Sung Hee, Lee, Song-Jae, Song, Seong-Won, Kim, Kyung, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Nam, Do-Hyun, Lee, Jeong-Won, Park, Keunchil, Kim, Kyoung-Mee, Lee, Jeeyun
Publicado 2020

Venadaparib Is a Novel and Selective PARP Inhibitor with Improved Physicochemical Properties, Efficacy, and Safety

por Lee, Myongjae, Je, In-Gyu, Kim, Jeong Eun, Yoo, Yeongran, Lim, Jong-Ha, Jang, Eunhye, Lee, Yoonsuk, Song, Dong Keun, Moon, An-Na, Kim, Jeong-Ah, Jeong, Jinah, Park, Joon-Tae, Lee, Jung Woo, Yang, Ji-Hoon, Hong, Chang-Hee, Park, Sun-Young, Park, Young-Whan, Baek, Nam Seok, Lee, Sungsook, Ha, Kyoung Soo, Choi, SungKu, Lee, Won Sik
Publicado 2023